{"@context":"https://schema.org","@graph":[{"@id":"https://thehippiescientist.net/compounds/cjc-1295/#entity","@type":["ChemicalSubstance","MolecularEntity"],"additionalProperty":[{"@type":"PropertyValue","propertyID":"evidence tier","value":"Preliminary evidence"},{"@type":"PropertyValue","propertyID":"evidence label","value":"D"},{"@type":"PropertyValue","propertyID":"AI entity completeness score","value":34}],"category":"GHRH analog peptide","description":"CJC-1295 is a synthetic growth hormone releasing hormone (GHRH) analog engineered for a longer half-life than natural GHRH, commonly combined with Ipamorelin in gray-market protocols; its GH/IGF-1 mechanism has early pharmaceutical-development data behind it, but no FDA approval and an uncertain compounding pathway.","identifier":[{"@type":"PropertyValue","propertyID":"THS entity id","value":"ths:compound:cjc-1295"},{"@type":"PropertyValue","propertyID":"THS slug","value":"cjc-1295"}],"mentions":[{"@id":"https://thehippiescientist.net/compounds/ipamorelin/#entity","@type":["ChemicalSubstance","Thing"],"additionalProperty":[{"@type":"PropertyValue","propertyID":"relationship type","value":"related-to"}],"name":"Ipamorelin","url":"https://thehippiescientist.net/compounds/ipamorelin/"}],"name":"CJC-1295","subjectOf":{"@id":"https://thehippiescientist.net/compounds/cjc-1295/#evidence-data"},"url":"https://thehippiescientist.net/compounds/cjc-1295/"},{"@id":"https://thehippiescientist.net/compounds/cjc-1295/#evidence-data","@type":"Article","about":{"@id":"https://thehippiescientist.net/compounds/cjc-1295/#entity"},"author":{"@type":"Person","name":"Willie B. Randolph III","url":"https://thehippiescientist.net/info/author/","@id":"https://thehippiescientist.net/info/author/#person","affiliation":{"@id":"https://thehippiescientist.net/#organization"}},"dateModified":"2026-06-30","dateReviewed":"2026-06-30","description":"CJC-1295 is a synthetic growth hormone releasing hormone (GHRH) analog engineered for a longer half-life than natural GHRH, commonly combined with Ipamorelin in gray-market protocols; its GH/IGF-1 mechanism has early pharmaceutical-development data behind it, but no FDA approval and an uncertain compounding pathway.","headline":"CJC-1295 evidence, safety, and entity data","mainEntity":{"@id":"https://thehippiescientist.net/compounds/cjc-1295/#entity"},"mentions":[{"@id":"https://thehippiescientist.net/compounds/ipamorelin/#entity","@type":["ChemicalSubstance","Thing"],"additionalProperty":[{"@type":"PropertyValue","propertyID":"relationship type","value":"related-to"}],"name":"Ipamorelin","url":"https://thehippiescientist.net/compounds/ipamorelin/"}],"publisher":{"@type":"Organization","name":"The Hippie Scientist","url":"https://thehippiescientist.net","@id":"https://thehippiescientist.net/#organization"},"url":"https://thehippiescientist.net/compounds/cjc-1295/"}]}